FDA Inspection 1263921 — Ingenus Pharmaceuticals GmbH
The FDA completed an inspection of Ingenus Pharmaceuticals GmbH on October 3, 2024 in Barbengo. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- October 3, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Barbengo (Switzerland)
Additional Details
Mutual Recognition Agreement (MRA)